Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Canertinib

384734fa-5e58-5a71-96d5-e746e7170a6f · FDA Trials Discontinued · targets ERBB2_HER2

Canertinib

MeasuredReference

Canertinib targets TXK, BLK, ERBB4_HER4. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

TXKBLKERBB4_HER4BMX_ETKERBB2_HER2

Top hallmarks

  • tumor promoting inflammation4.9k
  • evading apoptosis4.1k
  • proliferation3.9k

Top pathways disrupted

  • apical junction9.9k
  • allograft rejection9.8k
  • pi3k akt mtor signaling9.1k

Resistance landscape — Canertinib

MeasuredReference

No variant annotations found on Canertinib's top targets.

No variant annotations on Canertinib's top targets.
Open in new tab